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Abstract
BACKGROUND: Most attention and healthcare resources in Indonesia have been geared toward battling the 
coronavirus (CoV) disease (COVID)-19 pandemic, and less overture has been given to the looming risks of dengue 
that has been endemic in many areas of Indonesia. Despite related constraints, the Primary Health Cares (PHC) in 
Indonesia plays an important role in the face of emergency situations.
AIM: This study aimed to review the dengue and COVID-19 infection, clinical manifestations in children and adults, 
clinical pathology findings, as well as the prevention strategies that could be applied in PHC.
METHODS: This study is a narrative review based on the research articles and reports that were published between 
2010 and 2020. A total of 70 articles and reports were obtained and after careful consideration, 58 articles and 
reports were used as references of this study.
RESULTS: Both dengue virus (DENV) and severe acute respiratory syndrome-CoV (SARS-CoV-2) share the 
similarity of antigenic structure, common symptoms, and laboratory findings. The immune response in SARS-CoV-2 
may cause a cytokine storm, which can increase vascular permeability and organ damage. Secondary infection of 
DENV with different strains may allow the occurrence of antibody-dependent enhancement. The cross-reactions 
between SARS-CoV-2 antibodies and DENV antigens may cause false positive on rapid dengue infection serological 
tests.
CONCLUSION: PHC as the front line of health services has a fundamental role in the crisis situation. The prevention 
and control of DENV and SARS-CoV-2 infections are based on the mode of transmission and need compliance to 
the related health protocols.
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Introduction
The Indonesia’s healthcare system has been 
overwhelmed by the sudden struck of coronavirus 
(CoV) disease (COVID)-19 pandemic. After the first 
two confirmed cases of COVID-19 in Indonesia were 
reported in March 2, 2020 [1], the disease has spread 
rapidly to almost all parts of Indonesia that were totally 
unprepared for the crisis. Being the world’s fourth most 
populous nation [2], Indonesia might suffer immensely 
compared to less-populous countries [3]. Based on the 
rising cases, fatalities, and a large-scale socioeconomic 
impact, on April 13, 2020, the President declared 
COVID-19 as a national disaster in Indonesia [4].
Most attention and healthcare resources in 
Indonesia have been geared toward battling the COVID-
19 pandemic, and less overture has been given to the 
looming risks of dengue, despite the fact that dengue 
has been endemic in many areas of Indonesia and 
around the period of 1968-2009, Indonesia had a history 
of the highest cases of dengue hemorrhagic fever (DHF) 
in South East Asian region [5]. As of 9 July 2020, the 
Ministry of Health of the Republic of Indonesia revealed 
that five provinces with high cases of DHF also reported 
a high case fatality rate (CFR) of COVID-19, namely 
East Java (5948 DHF cases and COVID-19 CFR 7.3%), 
Special Capital Region of Jakarta (4227 DHF cases and 
COVID-19 CFR 5.0%), Central Java (2846 DHF cases 
and COVID-19 CFR 4.3%), West Java (10,772 DHF 
cases and COVID-19 CFR 3.8%), and Bali (8930 DHF 
cases and COVID-19 CFR 1.3%) [6], [7].
Both DHF and COVID-19 battle on two fronts 
of healthcare need. The heterogeneity of 514 districts 
in Indonesia by geographical features, demographical 
characteristics, cultures, local living styles, health-seeking 
behaviors, and community participations [8] creates 
challenges in the prevention and control strategies to 
combat the double burden of diseases. The introduction 
of universal health coverage with a single-payer system 
in 2014 that currently covers around 203 million people 
makes the Primary Health Care (PHC) Centres play 
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a significant role in the face of emergency situations. 
Accordingly, this study aimed to review the dengue and 
COVID-19 infection, clinical manifestations in children 
and adults, clinical pathology findings, as well as the 
prevention strategies that could be applied in PHC.
Search Strategy
This study is a review based on the research 
articles and reports related to dengue virus (DENV), 
pathogenesis of dengue, epidemiology of dengue in 
Indonesia, dengue prevention, COVID-19 virology and 
pathogenesis, COVID-19 and DHF clinical findings, 
COVID-19 and DHF clinical pathology findings, 
epidemiology of COVID-19 in Indonesia, and COVID-
19 prevention that were published between 2010 and 
2020. References from published articles were also 
included in the review, as long as they were published 
between 2010 and 2020. We excluded expert’s point of 
views. A total of 70 articles and reports were obtained 
and after careful consideration, 58 articles and reports 
were used as references of this study.
Epidemiology of DHF and COVID-19 in 
Indonesia
In Indonesia, DHF was first reported in Surabaya 
in 1968, with a high CFR of 41.38%. Dengue has spread 
to many areas in Indonesia and has become a public 
health concern since then [5]. DHF usually reaches its 
peak around March and diminish in the following months, 
which are the transition months between rainy and dry 
season. Nonetheless, during the COVID-19 pandemic, 
DHF cases in Indonesia have still been escalating with 
reports of more than 71,663 cases and 459 deaths from 
January to July 2020, even though the recorded cases 
and deaths were lower compared to reports from January 
to July 2019 with 112,954 cases and 751 deaths [6].
The incidence rate of DHF in Indonesia (red 
curve in Figure 1) seemed to increase in a span of half a 
century, from around 0.05 cases per 100,000 person-years 
in 1968 to around 77.96 cases per 100,000 person-years 
in 2016; with a peak of cyclic pattern occurring nearly 6–8 
years. In contrast, the annual CFR of DHF has decreased 
afterward (green curve in Figure 1), from more than 20% 
in 1968 to 0.79% in 2016 [9].
In the meantime, the Ministry of Health of the 
Republic of Indonesia recorded the increase number 
of COVID-19 confirmed cases from the first two cases 
reported in March 2, 2020, to 365,240 confirmed cases 
reported on October 19, 2020 (Figure 2). There was 
a sharp increase in attack rate (AR = percentage of 
confirmed cases by population size per 100,000 people) 
from 0.7% in March 2, 2020, to 136.4% in October 19, 
2020. The calculation was based on the estimated 
current population of Indonesia in 2020 (267,700,000 
people). There was a decrease of case positivity rate 
(CPR = percentage of confirmed cases by number of 
specimens tested) from 24.1% in April 2, 2020 to 14.3% 
in October 19, 2020; an increase of case recovery rate 
(CRR = percentage of recover cases by confirmed 
cases) from 6.3% in April 2, 2020 to 79.2% in October 
19, 2020; and a decrease of (CFR = percentage of 
death cases by confirmed cases) from 9.5% in April 
2, 2020 to 3.5% in October 19, 2020 [10]. Yet, the 
recorded COVID-19 data might not represent the 
number of actual infections, which could be undetected 
due to several factors, including lack of proper tracing 
and diagnoses [3].
Figure  2:  Number  of  coronavirus  disease-19  confirmed  cases, 
recover, death, RR, and CFR as of October 19, 2020 [10]
Epidemiological studies of COVID-19 may 
provide an insufficient representation of pediatric 
population. A study involving 582 children conducted 
in 25 European countries reported a CFR of 0.69%. 
Conversely, CFR in infants less than a month 
old to adolescents with COVID-19 reach 1.1% in 
Indonesia [11].
Dengue and severe acute respiratory 
syndrome-CoV (SARS-CoV-2) viruses
DENV belongs to the Flaviviridae, a family of 
positive, single-stranded, enveloped RNA viruses [12]. 
The transmission of DENV is mediated by mosquito 
vectors, Aedes spp. DENV consists of four serotypes, 
namely, DEN-1, DEN-2, DEN-3, and DEN-4 [13].
Dengue viral genome component (Figure 3) 
comprises genes that encode structural proteins and 
non-structural proteins. The structural protein genes 
contain codes to form protein M (membrane), C 
(capsid), and E (envelope), and these outer proteins 
Figure 1: Incidence rate (per 100,000 person-years) and case fatality 
rate (%) of dengue hemorrhagic fever in Indonesia from 1968 to 2017 [9]
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will bind to human antibodies. In contrast, the non-
structural protein genes contain codes to form enzymes 
that are needed for virus replication [14].
Virus that causes COVID-19 (SARS-CoV-2) is 
one of the Corona strains that infect humans (Figure 4). 
The CoV genome encodes four main proteins: spike 
(S), nucleocapsid (N), membrane (M), and envelope 
(E). S protein is responsible for the entry of viruses 
into cells that express angiotensin-converting enzyme 
2 (ACE2) receptors. Approximately 75% of the SARS-
CoV-2 genome is identical to the SARS-CoV genome, 
in which both viruses use ACE2 receptors to infect 
epithelial and endothelial barrier cells of the airway 
mucosa [17].
DENV Infection
Following infection, DENV replicates in the 
skin cells, including keratinocytes and Langerhans 
cells [18], which then trigger various host innate immune 
responses, including macrophage [19], [20], [21]. The 
bonding complex between receptors on the surface 
of cytotoxic T cells, major histocompatibility complex 
I (MHC I) molecules, virus peptides, and macrophage 
cells will act as antigen-presenting cells. After the 
bonding complex occurs, CD8 cells will produce 
cytokines, which will cause macrophage to undergo 
apoptosis [22], [23], [24]. Dengue may also infect mast 
cells, causing degranulation and release of several 
inflammatory mediators, which can increase vascular 
permeability and vascular leakage [25], [26].
The innate and adaptive immune response 
phases will determine the clinical symptoms that appear 
in infected patients. If both systems successfully kill 
the DENV, then there will be a low viremia or no virus 
so that the patient does not show clinical symptoms 
(subclinical). However, if the virus remains in moderate 
amounts (moderate viremia), then the clinical symptoms 
appear as dengue fever. If the virus escapes from the 
immune system and lead to severe viremia, then the 
clinical symptoms appear as dengue hemorrhagic 
fever, with life-threatening emergency symptoms, such 
as bleeding, shock, and death [13], [14], [15], [16], 
[17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27]. Figure 4: SARS-CoV-2 structure [15], [16]
Figure 3: (a-c) Dengue viral genome component [14]
a b
c
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DENV is also able to infect endothelial cells (Figure 5). 
The demise of endothelial cells by apoptosis will 
increase blood vessel permeability and cause plasma 
and red blood cell leakage, which is clinically seen as 
bleeding [28].
Figure 5: Pathogenesis of extra and intravascular bleeding [28]
Antibodies in dengue infection are produced by 
plasma cells derived from differentiation of B lymphocytes, 
by activation of CD4 cells through the intermediary 
molecule MHC II. Anti-dengue antibodies, part of host 
humoral pathways, are specific to DENV and will bind as 
lock and key to neutralize the virus [13]. The mechanism 
occurs in the first infection by DENV and secondary 
infection from the same serotype. However, if a secondary 
infection is caused by a different serotype of DENV 
(Figure 6), the antibodies assembled from the previous 
infection are not able to neutralize the virus from the second 
infection but will cause the fragment crystallizable region 
(Fc) antibody fragment to attach to antibody receptors on 
the macrophage cell surface. This attachment causes the 
entry of DENV into these cells and causes massive viral 
replication, increase in viral load, and release of several 
inflammatory mediators, which is referred to as antibody-
dependent enhancement (ADE). Clinical manifestations 
that occur are dengue hemorrhagic fever, dengue shock 
syndrome, or death [29], [30].
Figure 6: Pathogenesis of ADE in secondary dengue infection with 
different serotype [29]
SARS-CoV-2 Infection
When a CoV infects macrophage cells 
(Figure 7), NK cells as part of the innate immune 
system lyse both the infected macrophage cells and 
the viruses inside them. If macrophages fail to lyse 
the virus, they will activate CD4 cells. CD4 cells will 
differentiate into Th2 and Th1. Th1 cells will release 
inflammatory mediators to strengthen the role of 
macrophage cells. Whereas Th2 cells will help 
differentiate B lymphocyte cells into plasma cells and 
produce specific antibodies for this virus and then act 
as neutralizing antibodies [31], [32].
Figure 7: Immune response to coronavirus infection [32]
One of the main features of SARS-CoV-2 
infection is the emergence of cytokine storms that 
produce an uncontrolled systemic inflammatory 
response from the release of pro-inflammatory 
cytokines and chemokines by immune cells. Cytokine 
storms trigger severe inflammatory responses that 
cause acute respiratory distress syndrome, multiple 
organ failure, and death [17].
Dengue Fever and COVID-19 Infection
Previous research [33] proposed a possibility 
of viral interference mechanism [34] of SARS-CoV-2 
over DENV. SARS-CoV-2 has a high virulence and 
pathogenicity, and both SARS-CoV-2 and COVID-19 
have a tropism toward endothelial cells [35], [36], which 
could lead to competitive inhibition. Dengue fever and 
COVID-19 may have similar clinical symptoms in the 
early stages and similar laboratory features [37], [38]. 
COVID-19 cases may be misdiagnosed as dengue, 
especially when relying on DENV IgM, which can remain 
positive months after infection [39]. Some common 
symptoms observed in COVID-19 and dengue patients 
may include fever, malaise, myalgia, headaches, and 
weakness [40]. COVID-19 may also produce symptoms 
such as cough, dyspnea and dysgeusia, sore throat, 
anosmia, and diarrhea, whereas adult patients with 
dengue may also suffer from retro-orbital pain, nausea/
vomiting, rashes, and arthralgia [39].
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It is still puzzling why children with COVID-19 
suffer less severe symptoms than adults. A previous 
study suggested that children might be less sensitive 
to SARS-CoV-2 due to the maturity and function (e.g., 
binding ability) of ACE2 in children may be lower than 
that in adults. Further, the developing immune system 
in children may respond differently to pathogens [41].
Some common hematological findings 
in COVID-19 are lymphocytopenia, neutrophilia, 
eosinopenia, mild thrombocytopenia, and rarely 
thrombocytosis [42]. Neutrophil-lymphocyte ratio (NLR) 
in dengue fever is inversely correlated with the degree 
of severity, whereas NLR in COVID-19 is in line with 
the severity of the disease [43]. The increase in the 
inflammatory factor that occurs in COVID-19 may cause 
a decrease in erythrogenesis and cause erythrocyte 
destruction, which results in anemia [44]. In addition, 
coagulation abnormalities often occur in COVID-19, 
namely an increase in prothrombin time and d-dimer [45].
In dengue-endemic areas, there is also a 
possibility of false-positive results in serological tests 
for dengue fever. Due to the similarity of antigenic 
structure, SARS-CoV-2 can trigger the production of 
anti-DENV antibodies from immunological memory of 
T and B cells derived from previous exposure to the 
DENV virus. The anti-DENV antibodies against dengue 
may cause a false positive result of rapid dengue 
test and fail to consider COVID-19 infection, which 
leads to serious implications for both patients and 
public health [37]. Moreover, in patients with chronic 
co-morbidities, overlapping infections may increase the 
number of the patient requiring intensive care unit and 
mechanical ventilation [33].
Preventing DENV and SARS-CoV-2 
Transmission
A vaccine to prevent dengue is available in 
some countries for people ages 9–45 years old with 
confirmed prior DENV infection [46]. DHF prevention 
and control focus on breaking the life cycle of Aedes spp. 
mosquito vectors with biological, physical, and chemical 
approaches that have been part of national health 
programs and have been introduced to the community 
since 1968 [47]. The popular physical approach of DHF 
prevention in the community is to eradicate mosquito’s 
breeding place by draining water reservoirs once a 
week, covering water reservoir, and recycling used 
containers [48]. The application of biological agents, 
which are directed against the larval stages of dengue 
vectors, include fish (e.g., Gambusia affinis), bacteria 
(e.g., Bacillus thuringiensis), Cyclopods, and autocidal 
ovitraps. The chemical control may include chemical 
larviciding, insect growth regulators, and space sprays 
with organophosphate insecticides [49].
In contrast, SARS-CoV-2 may be transmitted 
primarily through contact, respiratory droplet (>5–
10 μm in diameter), and droplet nuclei (aerosol, 
≤5 μm in diameter) [50] when an infected person 
talks, coughs, sings, or sneezes [51]. However, 
it may also be possible to be transmitted through 
airborne [52], fomite (contaminated services) [53], 
fecal-oral [54], bloodborne, mother-to-child, and 
animal-to-human [55].
Many countries apply lockdown strategies to 
reduce the impact of COVID-19 pandemic [56]. PHC 
as the front line of health services has a fundamental 
role in the crisis situation, related to its knowledge of 
the catchment areas, accessibility, following up on 
suspected and mild cases that are directed toward 
restraining the pandemic and preventing the spread 
of the disease, as well as preventing the disease 
progression [56].
The prevention of COVID-19 may include 
washing hands with soap and water or an alcohol-
based hand sanitizer; maintaining physical distance 
between persons; avoid going to crowded places; and 
avoid touching eyes, nose, and mouth [57], [58]. The 
health protocols to prevent the transmission of SARS-
CoV-2 have been applied in workplaces, schools, 
health-care facilities, homes, and other public places in 
Indonesia [58], and compliance to the health protocols 
is needed.
Conclusion
Both DENV and SARS-CoV-2 share similarity of 
antigenic structure, common symptoms, and laboratory 
findings. The immune response in SARS-CoV-2 may 
cause cytokine storm, which can increase vascular 
permeability and organ damage. Secondary infection of 
DENV with different strains may allow the occurrence 
of ADE. The cross-reactions between SARS-CoV-2 
antibodies and DENV antigens may cause false 
positive on rapid dengue infection serological tests. 
DENV is transmitted by Aedes spp., whereas SARS-
CoV-2 may be transmitted through contact, respiratory 
droplet, aerosol, and other modes.
The sudden struck of COVID-19 pandemic 
and the surge of dengue causes a huge impact on 
health-care system in Indonesia. PHC as the front line 
of health services has a fundamental role in the crisis 
situation in restraining the pandemic and preventing the 
spread of the disease, as well as preventing the disease 
progression. The prevention and control of DENV and 
SARS-CoV-2 infections are based on the mode of 
transmission and need compliance to the related health 
protocols.
T1 - Thematic Issue “Coronavirus Disease (COVID-19)” Narrative Review Article
396 https://www.id-press.eu/mjms/index
Authors’ Contributions
Study design: WD and RB. Data acquisition: 
WD, RB, PAN, MFI, and VB. Drafting of manuscript: 
WD and RB. Critical revision of the manuscript: WD, 
RB, PAN, MFI, and VB.
References
1. Ministry of Health of the Republic of Indonesia. Recent Situation 
of Novel Coronavirus (COVID-19). Jakarta: Ministry of Health of 
the Republic of Indonesia; 2020.
2. The World Bank. The World Bank in Indonesia. Washington, D.C: 
The World Bank; 2020. p. 1.
3. Djalante R, Lassa J, Setiamarga D, Sudjatma A, Indrawan M, 
Haryanto B, et al. Review and analysis of current responses 
to COVID-19 in Indonesia: Period of January to March 2020. 
Prog Disaster Sci. 2020;6:100091. https://doi.org/10.1016/j.
pdisas.2020.100091
4. World Health Organization Indonesia. Coronavirus Disease 
2019 (COVID-19) Situation Report-4. Geneva: World Health 
Organization Indonesia; 2020.
5. Soepardi J, Brahim R, Hasnawati, Anggraeni ND, Ismandari F. 
Dengue Hemorrhagic Fever in Indonesia 1968-2009. Bul 
Jendela Epidemiol. 2010;2:1-13.
6. Ministry of Health of the Republic of Indonesia. Until July, 
Dengue Cases in Indonesia Reached 71 Thousand. Jakarta: 
Ministry of Health of the Republic of Indonesia; 2020. p. 1.
7. Ministry of Health of the Republic of Indonesia. Recent Situation 
of Novel Coronavirus (COVID-19). Data Reported Until 9 July 
2020. Jakarta: Ministry of Health of the Republic of Indonesia; 
2020. Available from: https://www.infeksiemerging.kemkes.
go.id/download/Situasi_Terkini_100720.pdf. [Last accessed on 
20 Oct 2020].
8. Agustina R, Dartanto T, Sitompul R, Susiloretni KA, Suparmi MK, 
Achadi EL, et al. Universal health coverage in Indonesia: Concept, 
progress, and challenges. Lancet. 2019;393(10166):75-102. 
https://doi.org/10.1016/s0140-6736(18)31647-7
 PMid:30579611
9. Harapan H, Michie A, Mudatsir M, Sasmono RT, Imrie A. 
Epidemiology of dengue hemorrhagic fever in Indonesia: 
Analysis of five decades data from the national disease 
surveillance. BMC Res Notes. 2019;12(1):350. https://doi.
org/10.1186/s13104-019-4379-9
 PMid:31221186
10. Ministry of Health of the Republic of Indonesia. COVID-19 
Update until 19 October 2020. Jakarta: Ministry of Health of 
the Republic of Indonesia; 2020. Available from: https://www.
infeksiemerging.kemkes.go.id.
11. Pulungan AB. The covid-19 pandemic and Asia-Pacific children. 
Asia Pac J Pediatr Child Health. 2020;3:57-8.
12. Centers for Disease Control and Prevention. Viral Hemorrhagic 
Fevers (VHFs). Flavivirus. Atlanta: Centers for Disease Control 
and Prevention; 2013. p. 1.
13. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: 
An integrated view. Clin Microbiol Rev. 2009;22(4):564-81. 
https://doi.org/10.1128/cmr.00035-09
 PMid:19822889
14. de Angel RM, Reyes-del Valle J. Dengue vaccines: Strongly sought 
but not a reality just yet. PLoS Pathog. 2013;9(10):e1003551. 
https://doi.org/10.1371/journal.ppat.1003551
 PMid:24098108
15. Schoeman D, Fielding BC. Coronavirus envelope protein: 
Current knowledge. Virol J 2019;16(1):69. https://doi.
org/10.1186/s12985-019-1182-0
 PMid:31133031
16. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. 
Characterization of the receptor-binding domain (RBD) of 2019 
novel coronavirus: Implication for development of RBD protein 
as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 
2020;17(6):613-20. https://doi.org/10.1038/s41423-020-0400-4
 PMid:32203189
17. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, 
cytokine storm and therapeutic potential of interferons. Cytokine 
Growth Factor Rev. 2020;53:66-70. https://doi.org/10.1016/j.
cytogfr.2020.05.002
 PMid:32418715
18. Garcia M, Wehbe M, Lévêque N, Bodet C. Skin innate 
immune response to flaviviral infection. Eur Cytokine Netw. 
2017;28(2):41-51. https://doi.org/10.1684/ecn.2017.0394
 PMid:28840835
19. Samuel CE. Antiviral actions of interferons. Clin Microbiol 
Rev. 2001;14(4):778-809. https://doi.org/10.1128/
cmr.14.4.778-809.2001
 PMid:11585785
20. Cha L, Berry CM, Nolan D, Castley A, Fernandez S, French MA. 
Interferon-alpha, immune activation and immune dysfunction 
in treated HIV infection. Clin Transl Immunol. 2014;3(2):e10. 
https://doi.org/10.1038/cti.2014.1
 PMid:25505958
21. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-
19 infection: Origin, transmission, and characteristics of 
human coronaviruses. J Adv Res. 2020;24:91-8. https://doi.
org/10.1016/j.jare.2020.03.005
 PMid:32257431
22. Laing K, Hutchinson F. “Immune Responses to Viruses”. 
London, United Kingdom: British Society for Immunology; 2014. 
Available from: https://www.immunology.org/public-information/
bitesized-immunology/pathogens-and-disease/immune-
responses-viruses. [Last accessed on 20 Oct 2020].
23. Mak T,  Saunders M, Jett B. “Immunity to Infection.” In: Primer 
to the Immune Response. 2nd ed. Cambridge, Massachusetts: 
Academic Cell; 2014. p. 295–332.
24. Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA. 
Immunity to viruses: Learning from successful human vaccines. 
Immunol Rev. 2013;255(1):243-55. https://doi.org/10.1111/
imr.12099
 PMid:23947360
25. Hasan S, Jamdar SF, Alalowi M, Al Ageel Al Beaiji SM. 
Dengue virus: A global human threat: Review of literature. 
J Int Soc Prev Community Dent. 2016;6(1):1-6. https://doi.
org/10.4103/2231-0762.175416
 PMid:27011925
26. St John AL. Influence of mast cells on dengue protective immunity 
and immune pathology. PLoS Pathog. 2013;9(12):e1003783. 
https://doi.org/10.1371/journal.ppat.1003783
 PMid:24367254
27. Rothman AL, Medin CL, Friberg H, Currier JR. 
Immunopathogenesis versus protection in dengue virus 
infections. Curr Trop Med Rep. 2014;1(1):13-20. https://doi.
org/10.1007/s40475-013-0009-0
 PMid:24883262
28. Wan SW, Wu-Hsieh BA, Lin YS, Chen WY, Huang Y, 
Anderson R. The monocyte-macrophage-mast cell axis in 
 Diarsvitri et al. Dengue Lurks During COVID-19 Pandemic
Open Access Maced J Med Sci. 2020 Nov 09; 8(T1):391-398. 397
dengue pathogenesis. J Biomed Sci. 2018;25(1):77. https://doi.
org/10.1186/s12929-018-0482-9
 PMid:30409217
29. Negro F. Is antibody-dependent enhancement playing a role in 
COVID-19 pathogenesis? Swiss Med Wkly. 2020;150:w20249. 
https://doi.org/10.4414/smw.2020.20249
 PMid:32298458
30. Ulrich H, Pillat MM, Tárnok A. Dengue fever, covid-19 (SARS-
CoV-2), and antibody-dependent enhancement (ADE): A 
perspective. Cytometry A. 2020;19(2):662-7. https://doi.
org/10.1002/cyto.a.24047
 PMid:32506725
31. Merad M, Martin JC. Pathological inflammation in patients 
with COVID-19: A key role for monocytes and macrophages. 
Nat Rev Immunol. 2020;20(6):355-62. https://doi.org/10.1038/
s41577-020-0331-4
 PMid:32376901
32. Mubarak A, Alturaiki W, Hemida MG. Middle east respiratory 
syndrome coronavirus (mers-cov): Infection, immunological 
response, and vaccine development. J Immunol Res. 
2019;2019:6491738. https://doi.org/10.1155/2019/6491738
33. Cardona-Ospina JA, Arteaga-Livias K, Villamil-Gómez WE, 
Pérez-Díaz CE, Bonilla-Aldana DK, Mondragon-Cardona A, 
et al. “Dengue and COVID-19, overlapping epidemics? An 
analysis from Colombia. J Med Virol. 2020. Available from: 
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26194. 
[Last accessed on 20 Oct 2020].
 PMid:32558962
34. Pinky L, Dobrovolny HM. Coinfections of the respiratory tract: Viral 
competition for resources. PLoS One. 2016;11(5):e0155589. 
https://doi.org/10.1371/journal.pone.0155589
 PMid:27196110
35. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-
Berg FM, et al. COVID-19 and the cardiovascular system: 
Implications for risk assessment, diagnosis, and treatment 
options. Cardiovasc Res. 2020;116(10):1666-87. https://doi.
org/10.1093/cvr/cvaa106
 PMid:32352535
36. Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. 
Lancet. 2019;393(10169):350-63. https://doi.org/10.1016/
s0140-6736(18)32560-1
 PMid:30696575
37. Yan G, Lee CK, Lam LT, Yan B, Chua YX, Lim AY, et al. Covert 
COVID-19 and false-positive dengue serology in Singapore. 
Lancet Infect Dis. 2020;20(5):536. https://doi.org/10.1016/
s1473-3099(20)30158-4
 PMid:32145189
38. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. 
Epidemiological and clinical characteristics of 99 cases of 2019 
novel coronavirus pneumonia in Wuhan, China: A descriptive 
study. Lancet. 2020;395(10223):507-13. https://doi.org/10.1016/
s0140-6736(20)30211-7
 PMid:32007143
39. Lokida D, Lukman N, Salim G, Butar DP, Kosasih H, Wulan WN, 
et al. Diagnosis of COVID-19 in a dengue-endemic area. Am 
J Trop Med Hyg. 2020;103(3):1220-2. https://doi.org/10.4269/
ajtmh.20-0676
 PMid:32762798
40. Lorenz C, Azevedo TS, Chiaravalloti-Neto F. COVID-19 and 
dengue fever: A dangerous combination for the health system 
in Brazil. Travel Med Infect Dis. 2020;35:101659. https://doi.
org/10.1016/j.tmaid.2020.101659
 PMid:32278756
41. Dong Y, Dong Y, Mo X, Hu Y, Qi X, Jiang F, et al. 
Epidemiology of COVID-19 among children in China. 
Pediatrics. 2020;145(6):e20200702. https://doi.org/10.1542/
peds.2020-0702
 PMid:32179660
42. de Oliveira Toledo SL, Nogueira LS, das Graças Carvalho M, 
Rios DR, de Barros Pinheiro M. COVID-19: Review and 
hematologic impact. Clin Chim Acta. 2020;510:170-6. https://
doi.org/10.1016/j.cca.2020.07.016
 PMid:32659224
43. Pimentel GD, Vega MC, Laviano A. High neutrophil to 
lymphocyte ratio as a prognostic marker in COVID-19 patients. 
Clin Nutr ESPEN. 2020. Available from: https://www.ncbi.nlm.
nih.gov/pmc/articles/PMC7427597/pdf/main.pdf. [Last access 
on 20 Oct 2020].
44. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, et al. Abnormalities 
of peripheral blood system in patients with COVID-19 in 
Wenzhou, China. Clin Chim Acta. 2020;507:174-80. https://doi.
org/10.1016/j.cca.2020.04.024
 PMid:32339487
45. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical 
features of patients infected with 2019 novel coronavirus in 
Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.
org/10.1016/s0140-6736(20)30183-5
 PMid:31986264
46. Centers for Disease Control and Prevention. Dengue vaccine 
globally. Atlanta: Centers for Disease Control and Prevention; 
2019. p. 1.
47. Kusriastuti R, Sutomo S. Evolution of dengue prevention and 
control programme in Indonesia. Dengue Bull. 2005;29:1-7.
48. Ministry of Health of the Republic of Indonesia. Beware of DHF, 
Prevent with 3M Plus. Jakarta: Ministry of Health of the Republic 
of Indonesia; 2020. p. 1.
49. World Health Organization. World Health Organization, and 
Regional Office for South-East Asia. Comprehensive Guidelines 
for Prevention and Control of Dengue and Dengue Haemorrhagic 
Fever. Revised and Expanded ed. SEARO Technical. Geneva: 
World Health Organization; 2011. p. 212.
50. World Health Organization. Infection Prevention and Control 
of Epidemic and Pandemic-prone Acute Respiratory Infections 
in Health Care. WHO Guidelines. Geneva: World Health 
Organization; 2014. p. 156.
51. Liu J, Liao X, Qian S, Yuan J, Wang F, Liu Y, et al. Community 
transmission of severe acute respiratory syndrome coronavirus 
2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26(6):1320-
3. https://doi.org/10.3201/eid2606.200239
 PMid:32125269
52. World Health Organizaton. Advice on the Use of Masks in the 
Context of COVID-19. Geneva: World Health Organizaton; 
2020. p. 16.
53. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, 
Gamble A, Williamson BN, et al. Aerosol and surface stability 
of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 
2020;382(16):1564-7. https://doi.org/10.1056/nejmc2004973
 PMid:32182409
54. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection 
of SARS-CoV-2 in different types of clinical specimens. JAMA. 
2020;323(18):1843-4. https://doi.org/10.1001/jama.2020.3786
 PMid:32159775
55. World Health Organization. Transmission of SARS-CoV-2: 
Implications for infection prevention precautions. Geneva: 
World Health Organization; 2020.
56. Sarti TD, Lazarini WS, Fontenelle LF, Almeida AP. What is 
the role of primary health care in the COVID-19 pandemic? 
Epidemiol Serv Saude. 2020;29(2):e2020166.
 PMid:32348404
T1 - Thematic Issue “Coronavirus Disease (COVID-19)” Narrative Review Article
398 https://www.id-press.eu/mjms/index
57. World Health Organization. Coronavirus Disease (COVID-19) Advice 
for the Public. Geneva: World Health Organization; 2020. p. 6.
58. Ministry of Health of the Republic of Indonesia. Minister of 
Health of the Republic of Indonesia Decree No. HK.01.07/
Menkes/382/2020 about Health Protocol for Communities in 
Public Places and Facilities to Prevent and Control Corona 
Virus Disease 2019 (COVID-19). Indonesia: Ministry of Health 
of the Republic of Indonesia; 2020. p. 66.
